TD Cowen Issues Positive Forecast for McKesson (NYSE:MCK) Stock Price

McKesson (NYSE:MCK) had its price objective lifted by analysts at TD Cowen from $1,006.00 to $1,200.00 in a research note issued to investors on Thursday, Benzinga reports. The brokerage presently has a “buy” rating on the stock. TD Cowen‘s price target points to a potential upside of 11.62% from the stock’s current price.

A number of other equities research analysts have also recently commented on MCK. Evercore reaffirmed an “outperform” rating and set a $950.00 price objective (down from $1,000.00) on shares of McKesson in a research note on Thursday, August 6th. Mizuho raised their price objective on shares of McKesson from $905.00 to $1,020.00 and gave the stock a “neutral” rating in a report on Tuesday, October 20th. Morgan Stanley set a $977.00 price target on McKesson in a research report on Tuesday, October 6th. Royal Bank Of Canada raised their price target on shares of McKesson from $845.00 to $965.00 and gave the stock a “sector perform” rating in a research note on Thursday. Finally, Bank of America lifted their price objective on shares of McKesson from $950.00 to $1,050.00 in a report on Thursday, August 6th. Fifteen analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $1,023.24.

McKesson Stock Performance

NYSE:MCK traded up $5.62 on Thursday, hitting $1,075.06. 886,800 shares of the stock were exchanged, compared to its average volume of 918,122. The stock has a market capitalization of $125.34 billion, a price-to-earnings ratio of 28.84, a P/E/G ratio of 1.99 and a beta of 0.27. McKesson has a 52 week low of $723.68 and a 52 week high of $1,121.50. The company’s 50-day moving average price is $931.17 and its 200 day moving average price is $865.74.

McKesson (NYSE:MCK) last issued its earnings results on Wednesday, November 4th. The company reported $11.68 earnings per share (EPS) for the quarter, beating the consensus estimate of $10.72 by $0.96. The company had revenue of $110.96 billion for the quarter, compared to analyst estimates of $109.90 billion. McKesson had a net margin of 1.12% and a negative return on equity of 253.21%. The company’s revenue for the quarter was up 7.5% on a year-over-year basis. During the same quarter last year, the firm earned $9.86 EPS. As a group, equities research analysts predict that McKesson will post 44.71 earnings per share for the current year.

Insider Transactions at McKesson

In related news, CAO Napoleon B. Rutledge, Jr. sold 111 shares of the business’s stock in a transaction on Tuesday, September 8th. The shares were sold at an average price of $891.45, for a total transaction of $98,950.95. Following the transaction, the chief accounting officer directly owned 521 shares in the company, valued at approximately $464,445.45. The trade was a 17.56% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Francisco Fraga sold 600 shares of the company’s stock in a transaction on Wednesday, November 4th. The stock was sold at an average price of $1,050.00, for a total transaction of $630,000.00. Following the sale, the executive vice president directly owned 5,064 shares in the company, valued at $5,317,200. This trade represents a 10.59% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 1,812 shares of company stock worth $1,794,182 in the last 90 days. Corporate insiders own 0.06% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the company. Nvwm LLC lifted its position in McKesson by 933.3% during the third quarter. Nvwm LLC now owns 31 shares of the company’s stock valued at $26,000 after purchasing an additional 28 shares during the last quarter. Delos Wealth Advisors LLC bought a new position in shares of McKesson in the 2nd quarter worth $27,000. Trellis Wealth Advisors LLC bought a new position in shares of McKesson in the 3rd quarter worth $32,000. GK Wealth Management LLC purchased a new stake in shares of McKesson during the 3rd quarter valued at $38,000. Finally, Curry Webb Wealth Management LLC purchased a new stake in shares of McKesson during the 3rd quarter valued at $38,000. 85.07% of the stock is currently owned by institutional investors and hedge funds.

More McKesson News

Here are the key news stories impacting McKesson this week:

• Positive Sentiment: Fiscal Q2 2027 adjusted earnings were $11.68 per share, ahead of analyst expectations, while revenue reached about $111 billion, also beating estimates and rising roughly 7.5% year over year. Q2 results and guidance
• Positive Sentiment: McKesson raised its fiscal 2027 adjusted EPS outlook to $45.60–$46.40. Management cited specialty-drug and GLP-1 distribution demand, higher prescription volumes, and operating gains as growth drivers. Earnings call highlights
• Positive Sentiment: Several analysts lifted price targets to $1,200, including Leerink Partners, TD Cowen and Evercore ISI, signaling confidence in the outlook. Leerink Partners rating TD Cowen target
• Neutral Sentiment: EVP Francisco Fraga sold 600 shares under a pre-arranged Rule 10b5-1 plan to cover tax withholding on vested equity awards. The stated purpose and planned nature of the sale may lessen its significance as a signal about his view of the company. SEC filing
• Negative Sentiment: RBC raised its target to $965 but kept a “sector perform” rating; that target remains below the share price cited in the report, reflecting a more cautious view of near-term upside. RBC rating

McKesson Company Profile

McKesson Corporation is a healthcare services and information technology company that distributes pharmaceuticals and medical products to pharmacies, hospitals, health systems, physicians and other healthcare providers. The company also provides technology, data and business solutions designed to support prescription management, pharmacy operations and patient care.

McKesson’s principal activities include pharmaceutical distribution, medical-surgical supply distribution, specialty pharmaceutical services and oncology care support.